Adcock of South Africa to Post Nine-Month Loss Amid Turnaround

Adcock Ingram Holdings Ltd. (AIP), South Africa’s largest supplier of hospital products, said it will record a nine-month loss as new management attempts to turn around the company after a failed takeover bid.

The drugmaker will post a basic and headline loss per share in the nine months through June, the Johannesburg-based company said in a statement today. Changes are being made to the structure of the business and the financial impact is still being assessed, it said. Adcock was the subject of a 10-month battle for control after profit margins came under pressure from rising production costs and a weaker rand in 2012.

The changes are “unlikely to yield significant improvement in the short term,” Adcock said. “The board however remains optimistic about the company’s long-term prospects.”

Adcock shares declined 0.4 percent to 52.10 rand as of the market close in Johannesburg, about 31 percent below the high end of a 74.50 rand to 75.78 rand takeover offer by CFR Pharmaceuticals SA (CFR) of Chile, which collapsed earlier this year. The stock has declined 27 percent in 2014, making it the fifth-worst performer on the FTSE/JSE Africa All Share Index.

CFR, Chile’s biggest drug maker, called off a 12.8-billion rand ($1.19 billion) cash and stock offer to buy Adcock after Johannesburg-based Bidvest Group Ltd. (BVT) built a blocking stake. Bidvest Chief Executive Officer Brian Joffe became Adcock’s new chairman with Kevin Wakeford becoming CEO.

To contact the reporter on this story: Kamlesh Bhuckory in Johannesburg at kbhuckory@bloomberg.net

To contact the editors responsible for this story: Simon Thiel at sthiel1@bloomberg.net John Bowker, David Risser

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.